In the study entitled "Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE" published in circulation in May 28, 2019, the authors concluded that Dapagliflozin appears to robustly reduces the risk of MACE in patients with type 2 diabetes mellitus and previous myocardial infarction. However when you look to the article you can not find a comparison table for the baseline characteristics of the study group and placebo group. So how can we be sure that this reported difference is truly because of the treatment intervention itself, rather than by differing prognostic characteristics in the sub-group?

More Rafik R. Elmehdawi's questions See All
Similar questions and discussions